Minaprine

Minaprine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N06AX07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	2-2.5 hours
Identifiers
	IUPAC name 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine;
CAS Number	25905-77-5 ;
PubChem CID	4199;
ChemSpider	4054 ;
UNII	00U7GX0NLM;
KEGG	D05039 ;
ChEMBL	ChEMBL278819 ;
CompTox Dashboard (EPA)	DTXSID5048477 ;
ECHA InfoCard	100.043.012
Chemical and physical data
Formula	C17H22N4O
Molar mass	298.390 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3;
	(what is this?)

Minaprine (INN, USAN, BAN) (brand names Brantur, Cantor) is a monoamine oxidase inhibitor antidepressant drug that was used in France for the treatment of depression until it was withdrawn from the market in 1996 because it caused convulsions.^[1]

A study found that it acts as a reversible inhibitor of MAO-A (RIMA) in rats.^[2] In a study it has also been found to weakly inhibit acetylcholinesterase in rat brain (striatum) homogenates.^[3]

References[]

^ Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.
^ Kan JP, Mouget-Goniot C, Worms P, Biziere K (March 1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–8. doi:10.1016/0006-2952(86)90085-7. PMID 3954800.
^ Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (February 1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–41. doi:10.1021/jm981101z. PMID 10052979.

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[Fung-2001-1] Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.

[2] Kan JP, Mouget-Goniot C, Worms P, Biziere K (March 1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–8. doi:10.1016/0006-2952(86)90085-7. PMID 3954800.

[3] Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (February 1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–41. doi:10.1021/jm981101z. PMID 10052979.

[1]

[2]

[3]

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	N06AX07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life	2-2.5 hours
Identifiers
IUPAC name 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
CAS Number	25905-77-5^Y
PubChem CID	4199
ChemSpider	4054^N
UNII	00U7GX0NLM
KEGG	D05039^Y
ChEMBL	ChEMBL278819^N
CompTox Dashboard (EPA)	DTXSID5048477
ECHA InfoCard	100.043.012
Chemical and physical data
Formula	C₁₇H₂₂N₄O
Molar mass	298.390 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
^NY (what is this?)